Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium

Campa, Daniele; Rizzato, Cosmeri; Capurso, Gabriele; Giese, Nathalia A.; Funel, Niccola; Greenhalf, William; Souček, Pavel; Gazouli, Maria; Pezzilli, Raffaele; Pasquali, Claudio; Talar-Wojnarowska, Renata; Cantore, Maurizio; Andriulli, Angelo; Scarpa, Aldo; Jamroziak, Krzysztof; Fave, Gianfranco Delle; Costello, Eithne; Khaw, Kay-Tee; Heller, Anette; Key, Tim; Theodoropoulos, George; Małecka‐Panas, Ewa; Mambrini, Andrea; Bambi, Franco; Landi, Stefano; Pedrazzoli, Sergio; Bassi, Claudio; Pacetti, Paola; Piepoli, Ada; Tavano, Francesca; Sebastiano, Pierluigi di; Vodičková, Ľudmila; Basso, Daniela; Plebani, Mario; Fogar, Paola; Büchler, Markus W.; Bugert, Peter; Vodička, Pavel; Boggi, Ugo; Neoptolemos, John P.; Werner, Jens; Canzian, Federico

doi:10.1016/j.dld.2012.09.014

Cited by 54 publications

(66 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comprehensive information on the control population was previously provided (18,19 (20). The EPIC-Oxford cohort comprises 65,429 people aged ≥20 years and living in the UK, recruited between 1993 and 1999 (21).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

et al. 2013

Self Cite

View full text Add to dashboard Cite

Abstract. There is strong epidemiologic evidence indicating that common genetic variability could be implicated in pancreatic cancer risk and, to date, various loci have been proposed. In particular, there is increasing evidence of the involvement of ABO gene variability and pancreatic cancer risk. In a large multicentric study of 1,028 pancreatic ductal adenocarcinoma cases and 2,257 controls in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium, we investigated the suggested association with increased risk for carriers of single nucleotide polymorphisms (SNPs) determining the A or B allele in comparison with the O allele, which encodes for a non-functional enzyme. Since glycosyltransferase activity, encoded by ABO, is higher for the A1 variant compared with the A2 variant, we investigated the hypothesis that A1 carriers were at an increased risk of pancreatic cancer. In our analysis, carriers of the A1 were indeed at greater risk of developing the disease. In addition, we investigated the possible influence that genetic variability at the ABO locus may have in pancreatic cancer survival, but we observed no effect in our population.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The study population was described in detail elsewhere (18,19). Briefly, 1,028 PDAC cases and 2,257 controls were collected retrospectively in five European countries in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium (18).…”

Section: Methodsmentioning

confidence: 99%

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Established risk factors for pancreas cancer are cigarette smoking, heavy alcohol consumption, preexisting diabetes mellitus (diagnosed at least 3 years before diagnosis of pancreatic cancer), obesity, chronic pancreatitis, and family history of pancreatic cancer (3,4). In addition, elevated fasting blood glucose levels (also within the nondiabetic range) and a small number of genetic polymorphic variants have been related to an increased risk (3,(5)(6)(7)(8)(9)(10)(11). Overall, however, these known risk factors can account for only a modest proportion of pancreas cancer occurrences, and taken together, they can provide only a very weak prediction of an individual's pancreas cancer risk.…”

Section: Introductionmentioning

confidence: 99%

Leukocyte Telomere Length in Relation to Pancreatic Cancer Risk: A Prospective Study

Campa

Mergarten

Vivo

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Background: Several studies have examined leukocyte telomere length (LTL) as a possible predictor for cancer at various organ sites. The hypothesis originally motivating many of these studies was that shorter telomeres would be associated with an increase in cancer risk; the results of epidemiologic studies have been inconsistent, however, and suggested positive, negative, or null associations. Two studies have addressed the association of LTL in relation to pancreatic cancer risk and the results are contrasting.Methods: We measured LTL in a prospective study of 331 pancreatic cancer cases and 331 controls in the context of the European Prospective Investigation into Cancer and Nutrition (EPIC).Results: We observed that the mean LTL was higher in cases (0.59 AE 0.20) than in controls (0.57 AE 0.17), although this difference was not statistically significant (P ¼ 0.07), and a basic logistic regression model showed no association of LTL with pancreas cancer risk. When adjusting for levels of HbA1c and C-peptide, however, there was a weakly positive association between longer LTL and pancreatic cancer risk [OR, 1.13; 95% confidence interval (CI), 1.01-1.27]. Additional analyses by cubic spline regression suggested a possible nonlinear relationship between LTL and pancreatic cancer risk (P ¼ 0.022), with a statistically nonsignificant increase in risk at very low LTL, as well as a significant increase at high LTL.Conclusion: Taken together, the results from our study do not support LTL as a uniform and strong predictor of pancreatic cancer.Impact: The results of this article can provide insights into telomere dynamics and highlight the complex relationship between LTL and pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev; 23(11); 2447-54. Ó2014 AACR.

show abstract

“…It is understood that pancreatic cancer undergoes a multistep process of increasing grades of dysplasia, and this process takes approximately 10 years before the neoplastic lesion becomes cancer. 21,22 As imaging techniques improve, neo plastic precursor lesions can be detected at an early stage, possibly decreasing the mortality from pancreatic cancer when screening programs are aimed at highrisk populations. Although they may not be costeffective at this time, these programs continue to be evaluated.…”

Section: Surgery For Precancerous Lesionsmentioning

confidence: 99%

“…A few, rare genetic disorders contribute up to 10%-15% of the cases. 21,22 The following diseases have demonstrated an association with an increased risk of pancreatic cancer. These diseases include PeutzJeghers polyposis, heredi tary pancreatitis, familial atypical multiple mole melanoma, Lynch syndrome or hereditary nonpolyposis colonic cancer, hereditary breastovarian cancer, familial adematous polypo sis, LiFraumeni, and familial pancreatic cancer (Table 1).…”

Section: Surgery For Precancerous Lesionsmentioning

confidence: 99%

Whipple procedure: patient selection and special considerations

Tan-Tam¹,

Segedi²,

Chung³

2016

OAS

View full text Add to dashboard Cite

At the inception of pancreatic surgery by Dr Whipple in 1930s, the mortality and morbidity risk was more than 20%. With further understanding of disease processes and improve ments in pancreas resection techniques, the mortality risk has decreased to less than 5%. Age and chronic illnesses are no longer a contraindication to surgical treatment. Life expectancy and quality of life at a later age have improved, making older patients more likely to receive pancreatic surgery, thereby also putting emphasis on operative patient selection to minimize complica tions. This review summarizes the benign and malignant illnesses that are treated with pancreas operations, and innovations and improvements in pancreatic surgery and perioperative care, and describes the careful selection process for patients who would benefit from an operation. These indications are not reserved only to Whipple operation, but to pancreatectomies as well.

show abstract

Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium

Cited by 54 publications

References 31 publications

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium

Leukocyte Telomere Length in Relation to Pancreatic Cancer Risk: A Prospective Study

Whipple procedure: patient selection and special considerations

Contact Info

Product

Resources

About